Familial Hypercholesterolemia: Diagnosis, Cascade Screening, Statin & PCSK9 Therapy

Cardiovascular Medicine · Guideline

Familial Hypercholesterolemia: Diagnosis, Cascade Screening, Statin & PCSK9 Therapy

By gomdori, MD · Evidence-based clinical guideline · Reviewed for AHA/ACC/EAS/NICE alignment

Executive Summary

Familial hypercholesterolemia (FH) is the most common autosomal dominant disorder of lipid metabolism — heterozygous FH affects 1 in 250 to 300 people worldwide (>30 million globally), and homozygous FH affects 1 in 250,000. FH is caused by pathogenic variants in LDLR (85-90 percent), APOB (5-10 percent), or PCSK9 gain-of-function (1-2 percent), resulting in lifelong elevation of LDL-C from birth. Untreated heterozygous FH leads to 13-fold higher coronary heart disease risk, with first myocardial infarction typically in the 4th to 5th decade for men and 6th decade for women; homozygous FH presents with cardiovascular events in childhood or adolescence. Diagnosis uses Dutch Lipid Clinic Network (DLCN >=8 = definite) or Simon Broome criteria, integrating LDL-C level, family history, physical findings (tendon xanthomas, corneal arcus), and genetic testing. Suspicion arises at any untreated LDL-C >=190 mg/dL in adults or >=160 mg/dL in children. Cascade screening of first-degree relatives is the most cost-effective public health intervention. Treatment requires high-intensity statin (atorvastatin 40-80 mg or rosuvastatin 20-40 mg) targeting >=50 percent LDL-C reduction; most patients require addition of ezetimibe and PCSK9 inhibitor (evolocumab, alirocumab, or inclisiran) to achieve LDL-C <70 mg/dL targets in those with established ASCVD. Statin therapy in children begins at age 8-10. Lipoprotein apheresis remains the cornerstone for homozygous FH, with new therapies (lomitapide, evinacumab) for refractory cases.
1:250
Heterozygous prevalence
>=190
Adult LDL trigger
13×
CHD risk untreated
50%
Inherited risk per child

S1. Genetics and Pathophysiology

Familial hypercholesterolemia is a Mendelian disorder of LDL receptor function. The LDL receptor (encoded by LDLR on chromosome 19p13) on hepatocyte surfaces binds circulating LDL particles through their apolipoprotein B-100 ligand, internalizes them via clathrin-coated pits, and delivers them to lysosomes where cholesterol is liberated for cellular metabolism. The released receptor recycles to the cell surface. Defective LDL receptor function reduces hepatic LDL clearance, raising plasma LDL-C concentration from birth and causing accelerated atherosclerosis lifelong.

Genes and Variants

Gene% of FHMechanismNotable variants
LDLR85-90%Defective LDL receptor (5 functional classes: null, defective transport, defective binding, defective internalization, defective recycling)>2,000 reported pathogenic variants. Class 1 null variants cause severe homozygous phenotype
APOB5-10%Defective LDL ligand reduces receptor bindingMost common variant p.Arg3527Gln (R3500Q in old nomenclature) — northern European
PCSK9 (gain of function)1-2%Increased PCSK9 enhances LDL receptor degradationp.Asp374Tyr most aggressive; p.Ser127Arg less severe
LDLRAP1 (autosomal recessive)RareDefective LDL receptor adaptor protein → impaired internalizationMostly Sardinian/Mediterranean

Heterozygous FH (one defective and one functional allele) reduces hepatic LDL clearance by ~40-50 percent, raising LDL-C 2-3 fold above baseline (typically 200-400 mg/dL untreated). Homozygous or compound heterozygous FH (two defective alleles) reduces clearance by 80-100 percent, raising LDL-C 6-10 fold (500-1,000+ mg/dL). Untreated homozygous FH causes severe atherosclerotic disease in childhood with frequent coronary events by adolescence and supravalvular aortic stenosis.

Loss-of-Function PCSK9: A Natural Experiment

The discovery that PCSK9 loss-of-function variants in West African and African American populations cause LIFETIME LDL-C reduction of 30-40 percent and 88 percent reduction in coronary disease risk (Cohen 2006 NEJM) provided the rationale for PCSK9 inhibitor development. PCSK9 normally binds the LDL receptor at the cell surface and chaperones it to lysosomal degradation; LOF variants prevent this, leaving more LDL receptor available to clear LDL. PCSK9 inhibitors mimic this protective natural variant.

Pathology

Cumulative LDL-C exposure (mg/dL × years) drives atherosclerosis risk. FH patients accumulate 50 mg/dL × year by birth, 1,000-2,000 mg/dL × year by age 20-30 — equivalent to 30+ years of average general-population LDL exposure. Tendon xanthomas form from cholesterol deposition in collagen-rich tendons (Achilles, extensor tendons of hand) — pathognomonic for FH but only present in 30-50 percent of heterozygous FH adults. Corneal arcus before age 45 also suggests FH. Xanthelasma (eyelid lipid deposits) is non-specific.

Familial Hypercholesterolemia — AD Inheritance Pattern Genetic pedigree chart showing autosomal_dominant inheritance pattern Familial Hypercholesterolemia — AD Inheritance Pattern I II III Male Female Affected Carrier
FH — Autosomal Dominant Inheritance + Cascade Screening

S2. Diagnosis: DLCN and Simon Broome Criteria

FH diagnosis combines clinical findings, family history, and (when available) genetic confirmation. Two validated clinical criteria sets:

Dutch Lipid Clinic Network (DLCN) Criteria

CriterionPoints
Family history
1st-degree relative with premature CHD/PVD (men <55, women <60)1
1st-degree relative with LDL-C >95th percentile1
1st-degree relative with tendon xanthoma OR child <18y with LDL-C >95th percentile2
Clinical history
Premature CHD (men <55, women <60)2
Premature cerebrovascular or peripheral vascular disease1
Physical examination
Tendon xanthoma6
Corneal arcus before age 454
LDL-C (untreated, mg/dL)
>=325 (>=8.5 mmol/L)8
251-325 (6.5-8.4 mmol/L)5
191-250 (5.0-6.4 mmol/L)3
155-190 (4.0-4.9 mmol/L)1
DNA analysis
Pathogenic variant in LDLR, APOB, or PCSK98

Interpretation: Definite FH >=8 points; Probable FH 6-8; Possible FH 3-5; Unlikely <3.

Simon Broome Criteria (UK)

Definite FH: Total cholesterol >290 mg/dL (>7.5 mmol/L) OR LDL-C >190 mg/dL (>4.9 mmol/L) in adults [or TC >260, LDL >155 in children <16] PLUS tendon xanthomas in patient OR first/second-degree relative OR DNA evidence of LDLR/APOB/PCSK9 mutation.

Possible FH: Same lipid criteria PLUS family history of MI before age 50 in second-degree relative or before 60 in first-degree relative OR family history of high cholesterol consistent with FH.

MEDPED (US) Criteria

Age- and family history-stratified LDL-C cutoffs:

Age1st-degree relative with FH2nd-degree3rd-degreeGeneral population
<20>=155 mg/dL>=165>=170>=200
20-29>=170>=180>=185>=220
30-39>=190>=200>=210>=240
>=40>=205>=215>=225>=260

Differential Diagnosis (Secondary Hypercholesterolemia)

Always rule out secondary causes before diagnosing FH:

  • Hypothyroidism (check TSH; hypothyroidism elevates LDL by reducing receptor expression — corrects with levothyroxine)
  • Nephrotic syndrome (urine protein/creatinine; albumin)
  • Cholestatic liver disease (ALP, GGT, bilirubin; primary biliary cholangitis)
  • Anorexia nervosa (paradoxical hypercholesterolemia from delayed clearance)
  • Medications (cyclosporine, glucocorticoids, antipsychotics, some HIV protease inhibitors, anabolic steroids, isotretinoin)
  • Pregnancy (LDL-C rises 25-50 percent; reverts after delivery — lipid testing best deferred)
  • Acute illness (lipids fall briefly during severe acute illness; defer LDL-C measurement 4-6 weeks)
  • Dysbetalipoproteinemia (Type III hyperlipoproteinemia) — APOE2/E2 with secondary trigger; tuboeruptive xanthomas, palmar crease xanthomas; both TC and TG elevated
  • Familial combined hyperlipidemia — variable lipid pattern across family, both LDL and TG elevated, no tendon xanthomas

Genetic Testing

Genetic testing identifies a pathogenic variant in 60-80 percent of clinically diagnosed FH (DLCN >=8). Negative testing does NOT exclude FH (variant may be in unstudied region or undiscovered gene). Testing is recommended for:

  • Index cases with definite FH (DLCN >=8 or Simon Broome) — establishes molecular diagnosis
  • Index cases with probable FH (DLCN 6-8) — may upgrade to definite
  • First-degree relatives of confirmed variant carrier — enables definitive cascade screening
  • Diagnostic confirmation before initiating PCSK9 inhibitor or pediatric statin therapy

Comprehensive panels include LDLR (full sequencing + deletion/duplication), APOB (selected exons covering ligand-binding region), PCSK9 (full sequencing). Insurance coverage variable.

S3. Cascade Screening of Relatives

Cascade screening — systematic identification and testing of first-degree relatives (parents, siblings, children) of an index FH case — is the single most cost-effective public health intervention in FH. Each first-degree relative has a 50 percent probability of inheriting heterozygous FH from an affected parent. Screening expands outward (relatives of newly identified cases are also screened), typically identifying 3 to 5 affected relatives per index case in well-functioning programs.

Implementation

For each index case:

  1. Counsel index patient about FH inheritance and importance of family screening (50 percent risk to each first-degree relative)
  2. Provide written family information letter for distribution
  3. Identify all first-degree relatives by name, age, contact (with patient consent)
  4. If pathogenic variant identified: offer targeted genetic testing for relatives (less expensive, definitive)
  5. If no variant identified: use age- and sex-specific LDL-C cutoffs (MEDPED criteria, age-specific 95th percentile) — heterozygous FH typically presents with LDL-C >180-190 mg/dL in adults, >130-150 mg/dL in children
  6. Refer affected relatives to lipid clinic or primary care for treatment initiation
  7. Continue cascade — screen first-degree relatives of newly identified cases

Pediatric Cascade Screening

Children of an FH parent should be screened by age 5 (some recommend by age 2), using non-fasting non-HDL or LDL-C. If affected, lifestyle counseling is initiated immediately and statin therapy started by age 8-10 (NLA, AHA, ESC consensus). Universal pediatric lipid screening at age 9-11 (NHLBI) is also recommended in the US — identifies FH cases missed by family history (de novo mutations or unknown family history). Bogalusa Heart Study and other autopsy studies of accidental deaths in children/young adults demonstrate fatty streaks in childhood and clinically silent atherosclerosis well before adulthood — supporting early intervention.

Programmatic Models

National cascade screening programs (Netherlands, Wales, Slovenia) have demonstrated population-level FH detection rates 40-70 percent (vs <10 percent in US currently). Key elements: universal index case database, dedicated nurse coordinators, genetic testing reimbursement, integrated EHR support, family communication tools. The FH Foundation in the US (thefhfoundation.org) provides patient-facing resources and supports cascade screening initiatives. Despite cost-effectiveness, US implementation lags due to fragmented healthcare, privacy concerns, and lack of dedicated funding.

✓ Cascade Screening Workflow Summary

  • For every index FH case: identify all first-degree relatives by name and age
  • Recommend lipid panel (with apoB if available) for all first-degree relatives
  • If known pathogenic variant in family: offer targeted genetic testing (faster, more definitive)
  • Children of FH parent: screen by age 5; treat by age 8-10 if affected
  • Continue cascade outward from each newly identified case
  • Average yield: 3-5 affected relatives per index case in established programs
  • Document family pedigree in chart for future cascade extension
FH Stepwise Treatment Surgical stepper: FH Stepwise Treatment FH Stepwise Treatment 1 Diagnosis + cascade Dutch Lipid Clinic Network score; genetic testing if score ≥6 OR proband identified; cascade screen 2 Statin (1st-line) High-intensity statin: rosuvastatin 40mg OR atorvastatin 80mg PO daily; start at age 8-10 in childre 3 Ezetimibe Ezetimibe 10mg PO daily — add if LDL not at goal (HeFH <70 mg/dL); reduces LDL additional 18-25% 4 PCSK9 inhibitors Alirocumab 75mg SC q2wk (max 150mg) OR evolocumab 140mg q2wk OR 420mg q4wk; reduce LDL additional 60 5 Inclisiran (small interfering RNA) Inclisiran 284mg SC at day 0, day 90, then q6mo — siRNA against PCSK9; sustained LDL reduction with 6 HoFH advanced therapy Evinacumab 15 mg/kg IV q4wk (ANGPTL3 inhibitor); lomitapide 5-60mg PO daily; LDL apheresis q1-2wk; l
FH Treatment Algorithm

S4. First-Line Therapy: High-Intensity Statin and Ezetimibe

Lipid Targets in FH

PopulationLDL-C TargetSource
FH adult, no ASCVD, no other major risk factor>=50% LDL reduction AND <100 mg/dL (<2.6 mmol/L)NLA, ACC
FH adult with ASCVD or DM>=50% LDL reduction AND <70 mg/dL (<1.8 mmol/L); consider <55 mg/dLNLA, ESC/EAS 2019 (<55)
FH child age >=8>=50% LDL reduction OR LDL-C <130 mg/dL (<3.4 mmol/L)AHA, NLA, ESC
Homozygous FHAggressive lowering required; target <100 (no ASCVD) or <70 mg/dL (with ASCVD); apheresis often neededEAS, AHA

High-Intensity Statins (First-Line)

High-intensity statins reduce LDL-C >=50 percent. Two agents qualify at high doses:

DrugHigh-intensity doseLDL reductionNotes
Atorvastatin40-80 mg PO daily50-55%Substrate of CYP3A4 — interactions with macrolides, azoles, grapefruit
Rosuvastatin20-40 mg PO daily55-63%Hydrophilic; minimal CYP metabolism; preferred in Asian patients (lower starting doses 5-10 mg)

Counsel: take in evening (most effective due to overnight cholesterol synthesis peak — though atorvastatin and rosuvastatin have long half-lives and can be taken at any time). Check baseline ALT and creatine kinase. Recheck lipids at 4-12 weeks; goal is >=50 percent LDL reduction.

Statin side effects:

  • Statin-associated muscle symptoms (SAMS): Reported by 5-10 percent of patients (RCT placebo-controlled rates similar — nocebo effect predominates). True myopathy with CK elevation in <0.1 percent. Rhabdomyolysis very rare. Strategy: rule out other causes (hypothyroidism, vitamin D deficiency, drug interactions), trial alternate-day or low-dose, switch statin (rosuvastatin and pravastatin have lowest myopathy signal), tolerate symptoms if mild, refer to lipid clinic if persistent.
  • Hepatotoxicity: ALT elevation 1-3 percent, usually transient. Discontinue if ALT >3× ULN. Routine ALT monitoring no longer recommended (FDA 2012) but baseline ALT prudent.
  • New-onset diabetes: Modest increase in T2DM incidence (1-2 cases per 100 person-years), greater with higher-intensity dosing and in patients with prediabetes. Cardiovascular benefit far outweighs diabetes risk.
  • Cognitive effects: Rare reports of memory/cognitive change. Large meta-analyses do not support causal association.

Ezetimibe (Add-On)

Inhibits intestinal NPC1L1 cholesterol absorption transporter. Ezetimibe 10 mg PO daily. Adds 18-24 percent LDL reduction on top of statin (insufficient as monotherapy in FH). Excellent safety profile, no significant drug interactions, no muscle side effects. IMPROVE-IT (NEJM 2015) showed simvastatin + ezetimibe reduced cardiovascular events 6.4 percent vs simvastatin alone. Most FH patients require statin + ezetimibe to approach LDL targets.

Lifestyle (Foundational But Insufficient Alone)

Mediterranean or DASH diet, saturated fat <7 percent kcal, trans fat avoidance, plant sterols/stanols 2 g/day (small additional 8-10 percent LDL reduction), soluble fiber 10-25 g/day, exercise >=150 min/week, no smoking, healthy weight. Lifestyle alone reduces LDL-C 10-15 percent — meaningful but inadequate for FH baseline 250-400 mg/dL.

S5. PCSK9 Inhibitors and Other Add-On Therapies

PCSK9 Monoclonal Antibody Inhibitors

DrugDoseLDL reductionCost (annual)
Evolocumab (Repatha)140 mg SC q2wk OR 420 mg SC monthly50-60%~$5,800-7,000
Alirocumab (Praluent)75 or 150 mg SC q2wk (or 300 mg SC monthly)50-60%~$5,800-7,000

Indications (FDA-approved):

  • Adults with heterozygous FH on maximum tolerated statin requiring additional LDL reduction
  • Adults with homozygous FH (evolocumab approved; LDL receptor activity must be present, even if reduced)
  • Adults with established cardiovascular disease requiring further LDL reduction
  • Approved in pediatric heterozygous FH (evolocumab age >=10)

Outcome trials: FOURIER (evolocumab, NEJM 2017) — 27,564 high-risk patients with prior MI/stroke/PAD on statin — evolocumab reduced primary composite (CV death, MI, stroke, hospitalization for UA, coronary revascularization) by 15 percent at median 2.2 years. ODYSSEY OUTCOMES (alirocumab, NEJM 2018) — 18,924 post-ACS patients on high-intensity statin — alirocumab reduced primary composite by 15 percent at 2.8 years.

Side effects: Injection site reactions (5-10 percent), nasopharyngitis, mild flu-like symptoms. No increase in neurocognitive events (EBBINGHAUS substudy specifically powered for cognition — no signal). No muscle symptoms. Can use in statin-intolerant patients.

Barriers to use: Cost ($5,800-7,000/year), complex prior authorization (typically requires documented FH or established ASCVD with maximum tolerated statin failure), patient self-injection or office administration logistics.

Inclisiran (Leqvio) — siRNA PCSK9 Silencer

Small interfering RNA targeting PCSK9 mRNA in hepatocytes. 284 mg SC at day 0, 3 months, then every 6 months (twice-yearly maintenance). Dose-dependent LDL reduction 50-55 percent. ORION-10 and ORION-11 trials demonstrated efficacy. Lower injection burden than monoclonal PCSK9 inhibitors (twice yearly vs every 2 weeks). FDA-approved 2021 for adults with heterozygous FH or established ASCVD on maximum tolerated statin. Cardiovascular outcomes trial (ORION-4) ongoing. Cost similar to monoclonal PCSK9 inhibitors. Less data than PCSK9 mAbs but emerging as preferred option for adherence/dosing simplicity.

Bempedoic Acid (Nexletol)

ATP-citrate lyase inhibitor (upstream of HMG-CoA reductase in cholesterol synthesis). 180 mg PO daily. Reduces LDL-C 17-21 percent monotherapy or 38 percent combined with ezetimibe (Nexlizet combo product). Activated only in liver (no muscle exposure) — useful in statin-intolerant patients. CLEAR Outcomes trial (NEJM 2023) demonstrated 13 percent reduction in major adverse cardiovascular events vs placebo in statin-intolerant patients. Side effects: hyperuricemia/gout, tendon rupture (rare), AKI, anemia, transaminitis. Modest LDL reduction limits use to add-on/alternative.

Lomitapide (for Homozygous FH only)

MTP (microsomal triglyceride transfer protein) inhibitor. Reduces LDL-C 40-50 percent in HoFH. Restricted REMS program due to hepatotoxicity (steatosis, transaminitis) and GI side effects (diarrhea, nausea, abdominal pain). Annual cost >$300,000. Reserved for HoFH patients on apheresis still failing target.

Evinacumab (Evkeeza)

Monoclonal antibody against ANGPTL3. 15 mg/kg IV every 4 weeks. Reduces LDL-C 50 percent in HoFH (effective even in receptor-negative HoFH where statins/PCSK9i fail). FDA-approved for HoFH age >=5. Annual cost ~$450,000.

LDL Apheresis (HoFH Cornerstone, Severe HeFH Refractory)

Extracorporeal lipoprotein removal every 1-2 weeks. Reduces LDL-C 60-75 percent acutely, returns toward baseline between sessions (mean LDL reduction 30-40 percent integrated). Indicated for HoFH (cornerstone), HeFH refractory to maximum medical therapy with established ASCVD, and elevated lipoprotein(a). Requires specialized apheresis center, vascular access, hours-long sessions.

When to Refer to Lipid Clinic / Cardiology

  • Definite FH diagnosis (DLCN >=8) — multidisciplinary management
  • Homozygous FH (always — apheresis, advanced therapies)
  • LDL-C remains above target despite high-intensity statin + ezetimibe
  • Statin intolerance precluding adequate LDL reduction
  • Established ASCVD plus FH — secondary prevention intensification
  • Pediatric FH — initiation of pediatric statin therapy and growth monitoring
  • Pregnancy planning in FH — preconception counseling, contraception during therapy
  • Considering PCSK9 inhibitor or inclisiran — diagnosis confirmation, prior authorization
  • Family screening coordination and pedigree mapping
  • Lipoprotein(a) >=50 mg/dL on top of FH — accelerated atherosclerosis

S6. Pediatric FH, Pregnancy & Homozygous FH

Pediatric FH Management

Children with FH show subclinical atherosclerosis on imaging by age 10-15 (carotid IMT thickening, coronary calcification rare but detectable). Lifestyle intervention initiated at diagnosis (any age). Statin therapy initiated at age 8-10 (per AHA, NLA, ESC consensus) — earlier in HoFH. Statins approved in pediatrics: pravastatin (>=8y), atorvastatin (>=10y), rosuvastatin (>=10y), simvastatin (>=10y), lovastatin (>=10y). Start low (atorvastatin 10 mg PO daily or rosuvastatin 5 mg PO daily), titrate as tolerated. Monitor growth, puberty, lipids quarterly. Long-term pediatric statin data (Kuipers JAMA 2014; 20-year follow-up of statins started in childhood) demonstrate cardiovascular event reduction without growth, sexual maturation, or developmental impact.

Pregnancy and FH

Statins are generally contraindicated in pregnancy (FDA category X — though 2021 FDA reclassification noted insufficient evidence for clinical teratogenicity, statins remain not recommended in pregnancy). Counsel reliable contraception during statin therapy. Pre-pregnancy: optimize LDL with statin, then discontinue 1-3 months before conception (consult with cardiology/lipid). During pregnancy: lifestyle only for most heterozygous FH. Bile acid sequestrants (cholestyramine, colesevelam) are pregnancy category B and may be used (limit to 4-6 g/day to avoid fat-soluble vitamin malabsorption). Lipoprotein apheresis safe in pregnancy and used in HoFH or severe HeFH with prior coronary disease. Resume statin postpartum after breastfeeding completion (or use bile acid sequestrants while nursing — minimal absorption).

Homozygous FH Management

HoFH presents in childhood with markedly elevated LDL-C (500-1,000+ mg/dL), tendon and tuberous xanthomas (often before age 5), supravalvular and root aortic stenosis, premature coronary disease (events possible by age 5-10 in untreated cases). Evaluation: Children with planar xanthomas (yellow/orange plaque-like skin lesions, especially over knees, elbows, hands), severe lipid abnormalities, or family history of HoFH require urgent referral to specialized center. Treatment combination:

  • Maximum tolerated statin + ezetimibe — modest benefit in HoFH due to baseline near-zero receptor activity
  • PCSK9 inhibitor (evolocumab) — works only if some residual receptor activity (defective alleles, not null/null)
  • Lipoprotein apheresis weekly or biweekly (cornerstone) — reduces LDL 60-75 percent acutely
  • Lomitapide (REMS program) for refractory cases
  • Evinacumab (newest, effective even in null/null genotype) — increasingly used
  • Inclisiran being studied in HoFH
  • Liver transplant in extreme cases (provides functional LDL receptors)
  • Aortic root replacement if supravalvular AS develops

Lipoprotein(a) Co-Testing

Measure Lp(a) at least once in every FH patient. Elevated Lp(a) (>=50 mg/dL or >=125 nmol/L) compounds ASCVD risk additively to LDL-C. Currently no specific therapy reduces Lp(a) substantially (statins paradoxically increase ~10 percent; PCSK9 inhibitors reduce ~25 percent; emerging RNA-based therapies pelacarsen and olpasiran in trials). Lp(a) at diagnosis informs cardiovascular risk and intensity of LDL lowering needed.

★ Pearl: The Untreated LDL-C "Index" Concept

Many FH patients are diagnosed AFTER starting a statin (referred for elevated lipids on routine screening, started on a statin, then referred for "high LDL despite statin"). Treated LDL-C significantly underestimates the patient's untreated baseline and may not meet DLCN/Simon Broome criteria. Calculate or estimate untreated LDL-C: divide treated LDL by (1 - expected fractional reduction). For atorvastatin 40 mg, expect ~50 percent reduction — divide treated LDL-C by 0.5. So patient on atorvastatin 40 mg with LDL 130 mg/dL has untreated baseline ~260 mg/dL — meeting FH criteria. This conversion enables retroactive FH diagnosis and unlocks cascade screening of relatives.

✗ Pitfall: Mistaking Achilles Tenderness for Tendinosis Instead of Xanthoma

Achilles tendon xanthomas are often misdiagnosed as tendinosis or partial tear in patients (often middle-aged) presenting with painful tendon thickening. Differentiating features: bilateral involvement (xanthomas typically symmetric), gradual painless thickening preceding any pain, palpable nodular thickening rather than diffuse tendinopathy, family history of premature CHD or hyperlipidemia, elevated LDL-C on screening. MRI or ultrasound of Achilles can help (xanthomas show multiple discrete hypoechoic deposits within tendon vs diffuse tendinosis). Missing this clue means missing FH — devastating for the patient and entire family. Always order lipid panel in any patient with bilateral Achilles thickening.

Frequently Asked Questions

When should familial hypercholesterolemia be suspected?
Suspect FH in any adult with untreated LDL-C >=190 mg/dL (>=4.9 mmol/L), in any child with untreated LDL-C >=160 mg/dL (>=4.1 mmol/L), in patients with premature ASCVD (men <55, women <60), tendon xanthomas (Achilles or extensor tendon), corneal arcus before age 45, or family history of premature coronary disease in first-degree relatives. The Dutch Lipid Clinic Network criteria (DLCN >=8 = definite, 6-8 = probable, 3-5 = possible) and Simon Broome criteria are validated tools for diagnosis. Untreated heterozygous FH (1 in 250-300 in most populations) shoulders 13-fold higher CHD risk; homozygous FH (1 in 250,000) presents with cardiovascular events in childhood/adolescence.
What genes cause familial hypercholesterolemia?
Three established autosomal dominant FH genes: LDLR (LDL receptor; ~85-90% of monogenic FH cases — >2,000 reported pathogenic variants), APOB (apolipoprotein B-100; ~5-10% — most common variant is p.Arg3527Gln, decreased LDL receptor binding), and PCSK9 (gain-of-function variants in ~1-2%). Recessive autosomal recessive hypercholesterolemia (ARH, gene LDLRAP1) is rare. Genetic testing identifies a pathogenic variant in 60-80% of clinically diagnosed FH; absence of identified variant does NOT exclude FH. Genetic confirmation enables definitive cascade screening of relatives.
What are LDL-C targets in familial hypercholesterolemia?
For FH adults without ASCVD: LDL-C reduction >=50% from baseline AND target <100 mg/dL (<2.6 mmol/L), per NLA and ACC. With established ASCVD: target <70 mg/dL (<1.8 mmol/L) with consideration of <55 mg/dL (<1.4 mmol/L) per ESC/EAS 2019. For children with FH: initiate statin at age 8-10, target LDL-C reduction >=50% or LDL-C <130 mg/dL (3.4 mmol/L). Most heterozygous FH adults will require combination therapy (statin + ezetimibe +/- PCSK9 inhibitor) to reach targets due to baseline LDL-C 250-400 mg/dL.
How does cascade screening work?
Cascade screening systematically tests first-degree relatives (parents, siblings, children) of an FH index case for elevated LDL-C and/or known familial pathogenic variant. Each first-degree relative has 50% probability of inheriting heterozygous FH. Once new cases are identified, screening expands to their first-degree relatives (so on outward through the family tree). Children of FH parent should be screened by age 5 with non-fasting non-HDL or LDL-C; if elevated, statin therapy initiated by age 8-10. Cascade screening is the most cost-effective public health intervention in FH — for every index case, ~3-5 affected relatives are identified, dramatically reducing premature ASCVD across the family. Programs in Netherlands, Wales, and Slovenia have demonstrated population-level impact.
When are PCSK9 inhibitors indicated?
PCSK9 inhibitors (evolocumab 140 mg SC every 2 weeks or 420 mg monthly; alirocumab 75-150 mg SC every 2 weeks; inclisiran 284 mg SC at 0, 3 months, then every 6 months) are indicated for: heterozygous FH adults with LDL-C >=70 mg/dL despite maximum tolerated statin + ezetimibe and established ASCVD, or LDL-C >=100 mg/dL without ASCVD; homozygous FH (evolocumab and inclisiran approved); statin-intolerant patients with very high cardiovascular risk. Reduce LDL-C 50-60% on top of statin, with FOURIER (evolocumab) and ODYSSEY OUTCOMES (alirocumab) showing 15% and 15% MACE reduction respectively. Major barriers are cost ($5,500-14,000/year) and prior authorization.

Practice Insights — FH Is Massively Underdiagnosed, Cascade Screening Saves Lives, Stack Therapy Aggressively, Start in Childhood

(The content below synthesizes published clinical patterns and expert consensus rather than first-person case reports.)After managing familial hypercholesterolemia across lipid clinic, preventive cardiology, and pediatric referral over many years, in experienced practice the three convictions are that FH is one of the most under-diagnosed treatable genetic disorders in medicine — ~1 in 250 people heterozygous for FH globally, yet only ~10% are diagnosed; primary care lipid screening systematically captures dyslipidemia but rarely triggers FH workup despite obvious red flags (LDL-C >190 in adult, family history of premature ASCVD, tendon xanthomas); that cascade screening of first- and second-degree relatives of every confirmed FH patient is the most cost-effective intervention available in clinical genetics — a single index case identification produces 4-10 additional diagnoses on average; and that aggressive multi-agent lipid-lowering (high-intensity statin → add ezetimibe → add PCSK9 inhibitor → consider inclisiran or bempedoic acid → lipoprotein apheresis for refractory cases) is non-negotiable because FH patients have lifetime cardiovascular risk 10-13× general population without treatment — every year of delayed treatment compounds atherosclerotic burden. Routinely, Experienced practice would rather initiate cascade screening at the index case diagnosis visit (request lipid panels on parents, siblings, children) than hope the relatives will eventually be screened by their own primary care doctors; in experienced hands the most preventable bad outcome Experience has shown was a 40-year-old FH patient (LDL-C 320 mg/dL untreated) who presented with first MI — both parents had died of premature MI but FH had never been considered as the family diagnosis.

Recognize FH Red Flags — Most Cases Are Missed

In experienced practice FH should be considered in any of these scenarios. Adult red flags: untreated LDL-C >190 mg/dL (4.9 mmol/L); LDL-C >160 with personal history of premature ASCVD (men <55, women <65); LDL-C >160 with family history of premature ASCVD in first-degree relative; tendon xanthomas (Achilles, dorsal hands — pathognomonic when present); corneal arcus before age 45; xanthelasmas in young adults. Pediatric red flags: LDL-C >160 (or >130 if known FH family); child of parent with FH (heterozygous → child has 50% probability). Diagnostic frameworks experienced practice uses: Dutch Lipid Clinic Network (DLCN) criteria — scores points for family history, clinical features, LDL level, genetic testing → "definite" (>8), "probable" (6-8), "possible" (3-5); Simon Broome criteria similarly score family + clinical + LDL. Genetic confirmation: LDLR, APOB, PCSK9 sequencing — confirms diagnosis in ~80% of clinically suspected FH; ~20% phenocopies remain genetically unconfirmed but treated as clinical FH. What experienced practice avoids: ascribing LDL >190 to "diet/lifestyle" without screening for FH; failing to investigate family history of premature MI; missing tendon xanthomas (palpation of Achilles tendon during physical exam is high-yield).

Cascade Screening — Highest-Yield Intervention in Lipid Clinic

Experienced practice would argue cascade screening of relatives is the highest cost-effectiveness intervention experienced clinicians perform. Process: index case identified → discuss family screening at first visit; provide patient with cascade screening letter to share with relatives; offer to coordinate with relatives' primary care providers; track follow-up of identified relatives. Who to screen: first-degree relatives (parents, siblings, children) — each has 50% probability if index is heterozygous; second-degree relatives if first-degree screening identifies additional cases. What to test: lipid panel; if elevated, genetic testing for the family-specific mutation (if known from index case — single mutation testing more cost-effective). Yield: average 1 index case identifies 4-10 additional relatives with FH; cascade is most cost-effective when family mutation known. Pediatric cascade: children of FH parent screened by age 2-10 (NLA recommends earlier than later — early statin treatment reduces lifetime cardiovascular risk); diet/lifestyle counseling immediately; statin initiation typically age 8-10 if LDL-C remains elevated. What experienced practice avoids: relying on patient's own communication to relatives without follow-up; missing the opportunity at index case visit (busy schedule excuse); failing to test children of confirmed FH parents.

Stack Therapy Aggressively — High-Intensity Statin → Ezetimibe → PCSK9 → More

in experienced hands FH treatment requires aggressive multi-agent therapy to achieve LDL goals. Step 1 — high-intensity statin: atorvastatin 40-80 mg or rosuvastatin 20-40 mg daily; target ≥50% LDL reduction. Most FH patients with this alone reach LDL ~120-180 mg/dL — usually insufficient. Step 2 — add ezetimibe: 10 mg daily; additional 18-25% LDL reduction; well-tolerated; mandatory step in FH before considering injectables. Step 3 — PCSK9 inhibitor: evolocumab 140 mg SC q2wk or 420 mg q4wk; alirocumab 75-150 mg SC q2wk; additional 50-60% LDL reduction on top of statin/ezetimibe; FOURIER and ODYSSEY trials demonstrated ASCVD event reduction in high-risk patients including FH. Step 4 — inclisiran: 284 mg SC initially, then 3 mo, then q6mo; siRNA suppressing hepatic PCSK9 synthesis; comparable LDL reduction to PCSK9 mAbs with twice-yearly dosing (compliance advantage). Step 5 — bempedoic acid: 180 mg PO daily; ATP-citrate lyase inhibitor (upstream of HMG-CoA reductase); useful for statin-intolerant; combination with ezetimibe achieves ~30-40% LDL reduction. LDL goals: <70 mg/dL for FH with established ASCVD or diabetes; <100 mg/dL for FH without ASCVD; some experts recommend <55 mg/dL for very high-risk FH (homozygous, multiple risk factors). What experienced practice avoids: accepting LDL 120-150 in FH patient as "good enough"; sequential monotherapy without stacking; reflexive PCSK9 inhibitor without ezetimibe trial first.

Special Cases — HoFH, Pregnancy, Pediatric, Homozygous

Experienced practice would say homozygous FH and special populations require specialty referral and individualized management. Homozygous FH (HoFH): 1 in 250,000-1 million; LDL-C typically >500 mg/dL untreated; aggressive premature ASCVD (often before age 20 if untreated); requires combination of statin + ezetimibe + PCSK9 inhibitor + lipoprotein apheresis (weekly or biweekly) + evinacumab (ANGPTL3 inhibitor, FDA 2021); some patients undergo liver transplant. Lipoprotein apheresis: extracorporeal LDL removal; performed weekly to biweekly; achieves dramatic LDL reduction but requires specialized centers. Pregnancy: statins contraindicated (FDA Category X — embryotoxic); LDL apheresis may be used for severe HoFH; postpartum reinstate medical therapy; breastfeeding contraindication to statins (excretion in breast milk). Pediatric FH: statin initiation typically age 8-10 if LDL-C >160 despite lifestyle (NLA, AAP); start with low-intensity statin and titrate; pravastatin and rosuvastatin best-studied in pediatrics; monitor growth and development; ezetimibe add at age 10+ if needed. Lp(a) testing: lipoprotein(a) is an independent ASCVD risk modifier; many FH patients also have elevated Lp(a); measure once in adult FH patients; emerging Lp(a)-lowering therapies (pelacarsen) in development.

Illustrative Scenario — late 45s Female with Untreated FH — Cascade Identified 5 Affected Relatives

(Composite teaching scenario assembled from published patterns; not an individual patient.)

A woman in her mid-40s presented for primary care evaluation after her sister had recent MI at age 47. Personal LDL-C 285 mg/dL on initial lipid panel; physical exam revealed Achilles tendon xanthomas bilaterally; family history significant for father MI at 52, paternal uncle MI at 49. FH diagnosis: DLCN score = 11 (definite); genetic testing confirmed LDLR mutation. Cascade screening initiated: lipid panels arranged for both adult children (ages 18 and 22), 2 siblings (the affected sister + 1 brother), and 2 nieces/nephews (children of affected sister). Results: son LDL-C 248 (positive); daughter LDL-C 142 (negative); brother LDL-C 295 (positive — already had MI at 51 but FH was never diagnosed); both children of affected sister positive (ages 16, 19, LDL-C 220 and 195). Total of 5 newly diagnosed FH cases from 1 index. Patient's own treatment: started rosuvastatin 40 mg daily + ezetimibe 10 mg daily — LDL-C reduced to 138 at 12 weeks; added evolocumab 140 mg SC q2wk — LDL-C reduced to 65 at additional 12 weeks. Sustained at LDL-C ~70 long-term. Family members: all started high-intensity statin + ezetimibe; PCSK9 inhibitor added where needed; pediatric niece/nephew followed in pediatric lipid clinic with low-intensity statin initiation per pediatric guidelines. Counseling: explained ~50% inheritance probability for offspring of each affected family member; longitudinal lipid clinic follow-up established for all.

Takeaway: One index FH diagnosis triggered cascade screening that identified 5 additional family members with FH — including the patient's brother who had already had MI at 51 without prior FH diagnosis. This kind of yield (1 index → 5+ relatives) is typical when cascade is systematically performed. Multi-agent stacked therapy (statin → ezetimibe → PCSK9 inhibitor) achieved aggressive LDL goal of <70 mg/dL. The opportunity cost of NOT performing cascade is generations of preventable premature cardiovascular events.

Protocol Tweaks Seasoned Clinicians Apply (Practice Refinements)

  1. Consider FH in any adult with LDL >190 or family history of premature ASCVD: DLCN or Simon Broome scoring; tendon xanthoma exam; genetic testing if clinically probable.
  2. Cascade screening at index visit: provide cascade letter; coordinate with relatives' PCPs; track follow-up; 1 index = 4-10 affected relatives identified on average.
  3. Stack therapy aggressively for FH: high-intensity statin → ezetimibe → PCSK9 inhibitor (or inclisiran) → bempedoic acid if statin intolerance → apheresis for refractory. Target LDL <70 with ASCVD; <100 without.
  4. Pediatric FH: start statin age 8-10 if elevated LDL: pravastatin or rosuvastatin best studied; monitor growth; HoFH needs evinacumab + apheresis at specialty centers.
Familial Hypercholesterolemia Personal Framework: Recognition + Cascade Screening + Stacked Therapy + Special Populations Personal framework for familial hypercholesterolemia covering red flag recognition, cascade screening of relatives, aggressively stacked multi-agent lipid-lowering therapy, and management of homozygous FH and pediatric populations Familial Hypercholesterolemia — Personal Framework 1. Recognize FH — 90% Missed Adult LDL >190 untreated → consider FH Family premature ASCVD (M<55, F<65) Tendon xanthomas (Achilles palpation!) Pediatric LDL >160 or FH parent + LDL >130 Score: DLCN or Simon Broome criteria Genetic: LDLR, APOB, PCSK9 (80% +) 2. Cascade Screening — Highest Yield 1 index → 4-10 additional FH dx Most cost-effective genetics intervention 1st degree: parents, siblings, children (50%) 2nd degree: if 1st-degree positive Single mutation test if family known Coordinate with relatives' PCPs · track Don't rely on patient communication alone 3. Stack Therapy Aggressively 1. High-intensity statin (atorva 40-80, rosu 20-40) 2. + Ezetimibe 10 mg (mandatory next step) 3. + PCSK9 inhibitor (evolocumab/alirocumab) 4. + Inclisiran (siRNA, q6mo) OR bempedoic acid 5. Lipoprotein apheresis (refractory/HoFH) Target LDL <70 ASCVD, <100 without 4. Special Populations HoFH (1/250k-1M): LDL >500 untreated + Apheresis + Evinacumab (ANGPTL3, FDA 2021) Pregnancy: statins CONTRAINDICATED LDL apheresis for severe HoFH; reinstate post-partum Pediatric: statin at age 8-10 if LDL >160 Pravastatin/rosuvastatin best studied; monitor growth Lp(a): measure once in adult FH Independent ASCVD risk; pelacarsen in development
FH framework: 90% of FH undiagnosed — recognize red flags (LDL >190, premature ASCVD family history, tendon xanthomas); cascade screening at index visit yields 4-10 additional affected relatives; aggressive multi-agent stacked therapy (statin → ezetimibe → PCSK9 → inclisiran/bempedoic acid → apheresis); pediatric and HoFH require specialty management.
GUIDELINE REFERENCES

Primary guideline documents this article draws on. Links resolve via DOI to the publisher; access may require a subscription.

Leave a Reply

Your email address will not be published. Required fields are marked *